Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marina Shvets

Podiatrist, Foot Surgery Rego Park, NY Doctor of Podiatric Medicine

NPI 1417118357 CMS profile 18440

6584 Austin St, 4U, Rego Park, NY 11374

Open in the dashboard

General payments

$448

16 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marina Shvets of Rego Park, NY is reported in the CMS Open Payments database as having received $448 across 16 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 42nd percentile of Podiatrist, Foot Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $132 3
2023 General $78 1
2022 General $55 2
2020 General $23 1
2019 General $161 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marina Shvets
  • Podiatrist, Foot Surgery median
  • Middle half of Podiatrist, Foot Surgery
  • National median

In program year 2025, general payments to Marina Shvets were reported at $132. Among 732 Podiatrist, Foot Surgery profiles paid that year, the median was $180 and the middle half received between $70 and $569.

Show as a table
Year Marina Shvets Podiatrist, Foot Surgery median Middle half National median
2019 $161 $167 $67–$484 $163
2020 $23 $114 $40–$323 $114
2021 $0 $171 $57–$502 $132
2022 $55 $196 $66–$556 $149
2023 $78 $187 $78–$466 $160
2024 $0 $190 $78–$557 $164
2025 $132 $180 $70–$569 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $141 8 payments
  2. Next Science LLC $102 2 payments
  3. Djo, LLC $78 1 payment
  4. Smith+Nephew, Inc. $76 3 payments
  5. AbbVie, Inc. $31 1 payment
  6. Amgen Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $448 16 payments
Products named General payments · program years 2019–2025
  1. ANORO $141 8 payments
  2. XPERIENCE $102 2 payments
  3. BlastX $102 2 payments
  4. CMF $78 1 payment
  5. COLLAGENASE SANTYL $54 2 payments
  6. REGRANEX Pharma Products $54 2 payments
  7. SYNTHROID $31 1 payment
  8. REGRANEX Pharma Product $23 1 payment
  9. Santyl $23 1 payment
  10. AIMOVIG $20 1 payment
  11. Other $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

2,256

Median for Podiatry: 160

Drug cost

$164,623

Median for Podiatry: $2,368

Branded share of claims

21%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jublia Efinaconazole Brand 34 $49,090
Diclofenac Sodium Generic 238 $46,012
Ketoconazole Generic 238 $11,491
Fluocinonide Generic 93 $8,327
Ammonium Lactate Generic 436 $8,032
Clotrimazole Generic 217 $6,753
Lidocaine Generic 41 $5,792
Ciclopirox Ciclopirox Olamine Brand 111 $5,495
Ciclopirox Generic 144 $5,343
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 216 $3,950

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$155,586

Of which drugs: $50

Medicare patients

512

Average age 77

Services billed

3,104

292 women, 220 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 63%
Ischemic heart disease 53%
Depression 35%
Chronic kidney disease 29%
Heart failure 28%
COPD 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 53 $41
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 13 104 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

16 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record